Stockreport

How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story [Yahoo! Finance]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF zanzalintinib with and without an immune checkpoint inhibitor in intersected stage II/III colorectal cancer, using Signatera to track circulating tumor DNA in a high-ris [Read more]